Physician profile
Lilian U Ogujiofor
NPI 1255635058
$8,298.98
in general payments reported to CMS, 2019-2025
22 companies · $3,807 in 2025
The $3,807 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.69 · 2023: $1,766 · 2024: $2,705 · 2025: $3,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,278.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,672.11 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $916.79 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $910.99 | 2023-2025 | |
| Alkermes, INC. | $898.99 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $728.32 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $615.21 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $498.71 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $447.78 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $432.48 | 2024-2025 | Spravato, Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $367.45 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $142.87 | 2024-2025 | Qelbree |
| Lundbeck LLC | $118.71 | 2023-2025 | Rexulti |
| Eisai INC. | $117.39 | 2023 | |
| Neuronetics, INC. | $106.92 | 2024 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $98.53 | 2024-2025 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $76.32 | 2024-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $44.49 | 2023-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $34.04 | 2023 | Belsomra |
| Boston Scientific Corporation | $27.86 | 2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $20.69 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.55 | 2025 | Relexxii |
| Corium, LLC | $7.78 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilian Ogujiofor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.